Catching the therapeutic window of opportunity in early crohn’s disease

Silvio Danese, Gionata Fiorino, Carlos Fernandes, Laureal Peyrin-Biroulet

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Crohn’s disease (CD) is a chronic, disabling, progressive and destructive disease. The general goal of conventional step-up strategy in CD treatment is to treat and control symptoms. This strategy did not change the disease course and is now being replaced with a treat-to-target approach. Achieving deep remission (clinical remission and absence of mucosal ulcerations) is the target in CD in 2014. Inducing and maintaining deep remission is needed to prevent long-term outcomes such as bowel damage and disability in CD. Diagnostic delay is a common issue in CD and is associated with an increased risk of bowel damage over time. Identification of poor prognostic factors, risk stratification together with the development of “red flags” may result in early intervention with disease-modifying agents such as anti-TNF agents with the final aim of preventing overtreatment and avoiding undertreatment. Similar to rheumatoid arthritis, by catching the therapeutic window of opportunity in early CD and achieving deep remission, this could be the best way to change disease course (hospitalizations, surgeries, bowel damage, and disability) and patients’ life.

Original languageEnglish
Pages (from-to)1056-1063
Number of pages8
JournalCurrent Drug Targets
Volume15
Issue number11
Publication statusPublished - Jan 1 2014

Fingerprint

Crohn Disease
Therapeutics
Rheumatoid Arthritis
Hospitalization
Surgery

Keywords

  • Crohn’s disease
  • Early disease
  • Inflammatory bowel disease
  • Therapy

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Catching the therapeutic window of opportunity in early crohn’s disease. / Danese, Silvio; Fiorino, Gionata; Fernandes, Carlos; Peyrin-Biroulet, Laureal.

In: Current Drug Targets, Vol. 15, No. 11, 01.01.2014, p. 1056-1063.

Research output: Contribution to journalArticle

Danese, S, Fiorino, G, Fernandes, C & Peyrin-Biroulet, L 2014, 'Catching the therapeutic window of opportunity in early crohn’s disease', Current Drug Targets, vol. 15, no. 11, pp. 1056-1063.
Danese, Silvio ; Fiorino, Gionata ; Fernandes, Carlos ; Peyrin-Biroulet, Laureal. / Catching the therapeutic window of opportunity in early crohn’s disease. In: Current Drug Targets. 2014 ; Vol. 15, No. 11. pp. 1056-1063.
@article{4721be0c910f475a9c42cd84caed4d13,
title = "Catching the therapeutic window of opportunity in early crohn’s disease",
abstract = "Crohn’s disease (CD) is a chronic, disabling, progressive and destructive disease. The general goal of conventional step-up strategy in CD treatment is to treat and control symptoms. This strategy did not change the disease course and is now being replaced with a treat-to-target approach. Achieving deep remission (clinical remission and absence of mucosal ulcerations) is the target in CD in 2014. Inducing and maintaining deep remission is needed to prevent long-term outcomes such as bowel damage and disability in CD. Diagnostic delay is a common issue in CD and is associated with an increased risk of bowel damage over time. Identification of poor prognostic factors, risk stratification together with the development of “red flags” may result in early intervention with disease-modifying agents such as anti-TNF agents with the final aim of preventing overtreatment and avoiding undertreatment. Similar to rheumatoid arthritis, by catching the therapeutic window of opportunity in early CD and achieving deep remission, this could be the best way to change disease course (hospitalizations, surgeries, bowel damage, and disability) and patients’ life.",
keywords = "Crohn’s disease, Early disease, Inflammatory bowel disease, Therapy",
author = "Silvio Danese and Gionata Fiorino and Carlos Fernandes and Laureal Peyrin-Biroulet",
year = "2014",
month = "1",
day = "1",
language = "English",
volume = "15",
pages = "1056--1063",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "11",

}

TY - JOUR

T1 - Catching the therapeutic window of opportunity in early crohn’s disease

AU - Danese, Silvio

AU - Fiorino, Gionata

AU - Fernandes, Carlos

AU - Peyrin-Biroulet, Laureal

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Crohn’s disease (CD) is a chronic, disabling, progressive and destructive disease. The general goal of conventional step-up strategy in CD treatment is to treat and control symptoms. This strategy did not change the disease course and is now being replaced with a treat-to-target approach. Achieving deep remission (clinical remission and absence of mucosal ulcerations) is the target in CD in 2014. Inducing and maintaining deep remission is needed to prevent long-term outcomes such as bowel damage and disability in CD. Diagnostic delay is a common issue in CD and is associated with an increased risk of bowel damage over time. Identification of poor prognostic factors, risk stratification together with the development of “red flags” may result in early intervention with disease-modifying agents such as anti-TNF agents with the final aim of preventing overtreatment and avoiding undertreatment. Similar to rheumatoid arthritis, by catching the therapeutic window of opportunity in early CD and achieving deep remission, this could be the best way to change disease course (hospitalizations, surgeries, bowel damage, and disability) and patients’ life.

AB - Crohn’s disease (CD) is a chronic, disabling, progressive and destructive disease. The general goal of conventional step-up strategy in CD treatment is to treat and control symptoms. This strategy did not change the disease course and is now being replaced with a treat-to-target approach. Achieving deep remission (clinical remission and absence of mucosal ulcerations) is the target in CD in 2014. Inducing and maintaining deep remission is needed to prevent long-term outcomes such as bowel damage and disability in CD. Diagnostic delay is a common issue in CD and is associated with an increased risk of bowel damage over time. Identification of poor prognostic factors, risk stratification together with the development of “red flags” may result in early intervention with disease-modifying agents such as anti-TNF agents with the final aim of preventing overtreatment and avoiding undertreatment. Similar to rheumatoid arthritis, by catching the therapeutic window of opportunity in early CD and achieving deep remission, this could be the best way to change disease course (hospitalizations, surgeries, bowel damage, and disability) and patients’ life.

KW - Crohn’s disease

KW - Early disease

KW - Inflammatory bowel disease

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84925857082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925857082&partnerID=8YFLogxK

M3 - Article

C2 - 25198784

AN - SCOPUS:84925857082

VL - 15

SP - 1056

EP - 1063

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 11

ER -